Loading
A phase 2 trial of SHR-8068, Adebrelimab, Bevacizumab in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer is a phase 2 interventional study registered as NCT07071714 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 103 participants enrolled, started 2025-07-22 and due to reach its primary completion in 2031-10. Interventions recorded: SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Colorectal cancer.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.